Chronic fatigue is a life-altering symptom that can have multiple root causes, ranging from viral infections and immune dysfunction to tick-borne illnesses like Lyme disease. For patients navigating this complex landscape, testing for specific immune markers such as CD57 can provide valuable insights. But what exactly is the CD57 test, and how does it relate to chronic fatigue and conditions like Lyme disease? Let’s explore.

What is CD57?

CD57 is a marker found on a subset of natural killer (NK) cells, which are vital components of your immune system. NK cells are responsible for targeting and destroying harmful invaders like bacteria, viruses, and even abnormal cells. The CD57 marker identifies a specific type of NK cell that plays an important role in immune defence against persistent bacterial infections, including Borrelia burgdorferi, the bacterium that causes Lyme disease.

Why is CD57 Important in Fatigue-Related Conditions?

Chronic fatigue conditions often involve immune system dysregulation, where the body’s defence mechanisms are impaired or overactive. CD57 testing helps assess how well your immune system is functioning and whether it might be under strain due to infections or other stressors. Here’s why it’s particularly relevant:

1. Chronic Lyme Disease CD57 testing is often used in cases of suspected chronic Lyme disease, especially when standard diagnostic tests (like Lyme Western Blot or ELISA) are inconclusive

• Chronic Lyme disease can suppress CD57 levels, leading to low CD57 counts in blood tests. This suppression reflects immune system dysfunction caused by the long-term presence of Borrelia bacteria.
• A low CD57 count (typically below 100 cells/μL) may suggest ongoing infection or inflammation, which can contribute to debilitating fatigue.

2. Monitoring Lyme Disease Treatment For patients undergoing treatment for Lyme disease, CD57 levels can help monitor progress.

• If CD57 counts increase during treatment, it may indicate that the immune system is recovering and regaining its ability to fight the infection.

3. Broader Immune Dysfunction Low CD57 levels are not exclusive to Lyme disease. They may also occur in conditions involving chronic immune suppression or dysfunction, such as viral reactivations (e.g., Epstein-Barr virus or Cytomegalovirus) or other chronic infections.

4. Distinguishing Causes of Fatigue CD57 testing is a useful piece of the diagnostic puzzle when exploring the root causes of fatigue. It is often used alongside other tests, such as the Lyme Ellispot, adrenal stress testing, and thyroid function panels, to build a comprehensive picture of a patient’s health.

How is the CD57 Test Performed?

CD57 testing is a simple blood test. Your doctor will measure the number of CD57+ NK cells in your blood and assess whether the count is low, normal, or high. It’s important to note that:

• Results can vary between labs due to differences in testing methods.
• The interpretation of CD57 levels should always consider your overall clinical picture, including symptoms and other test results.

Limitations of CD57 Testing

While CD57 testing can provide valuable insights, it’s not a standalone diagnostic tool. Here are some key limitations:

• Not Lyme-Specific: A low CD57 count does not confirm Lyme disease, nor does a normal count rule it out.
• Non-Specific: Low CD57 levels can also occur in other conditions, such as viral infections or autoimmune disorders.
• Variability: Test results may vary between individuals and labs, so trends over time may be more useful than a single result.

Because of these limitations, CD57 testing is most effective when used as part of a broader diagnostic strategy.

Should You Consider CD57 Testing?

CD57 testing may be worth exploring if you have:

• Symptoms suggestive of chronic Lyme disease, such as fatigue, joint pain, brain fog, or neurocognitive issues.
• Persistent fatigue with no clear explanation, especially if other infections or immune dysregulation are suspected.
• A need to monitor progress during treatment for Lyme disease or other chronic infections.

What Does CD57 Testing Mean for Your Treatment?

If your CD57 levels are low, your healthcare provider may consider:

• Targeting Persistent Infections: Treatment may focus on addressing underlying infections, such as Borrelia, Babesia, or Bartonella.
• Supporting Immune Function: Therapies aimed at improving immune resilience, such as lifestyle changes, supplements, and medications, may be recommended.
• Monitoring Progress: Repeat testing over time can help track how your immune system responds to treatment.

Conclusion

CD57 testing is a valuable tool for understanding immune function in chronic fatigue conditions, particularly when Lyme disease or other persistent infections are suspected. While it has its limitations, CD57 testing can provide useful information to guide diagnosis and treatment. As with any test, its results should be interpreted in the context of your overall health, symptoms, and other diagnostic findings.

If you’re struggling with chronic fatigue and looking for answers, consider speaking with a functional medicine practitioner who can create a tailored plan to uncover the root causes of your condition and support your recovery.

References:

• Stricker, R. B., & Winger, E. E. (2001). Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. Immunology Letters, 76(1), 43–48. https://doi.org/10.1016/S0165-2478(00)00316-3
• Wormser, G. P., Dattwyler, R. J., Shapiro, E. D., Halperin, J. J., Steere, A. C., Klempner, M. S., et al. (2006). The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases, 43(9), 1089–1134. https://doi.org/10.1086/508667
• Katchar, K., Drouin, E. E., & Steere, A. C. (2013). Natural killer cells and natural killer T cells in Lyme arthritis. Arthritis Research & Therapy, 15(R183). https://doi.org/10.1186/ar4373
• Stricker, R. B., & Winger, E. E. (2009). Natural killer cells in chronic Lyme disease. Clinical and Vaccine Immunology, 16(11), 1704. https://doi.org/10.1128/CVI.00260-09
• Aucott, J. N., Rebman, A. W., Crowder, L. A., & Kortte, K. B. (2013). Post-treatment 
• Lyme disease syndrome symptomatology and the impact on life functioning: Is there something here? Quality of Life Research, 22(1), 75–84. https://doi.org/10.1007/s11136-012-0126-6